Loading...
Exagen Community
NasdaqGM:XGN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
Community Investing Ideas
Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic Portfolio
Key Takeaways Expanding test offerings, sales reach, and clinical validation position Exagen for significant market growth, margin improvement, and broader reimbursement. Strategic biopharma collaborations, disciplined operations, and digital integration support scalable, high-margin revenue and sustained earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$14
31.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
14.51% p.a.
Profit Margin
16.28%
Future PE
29.79x
Share price in 2028
US$9.9